Lorena Paduraru, Andrei Vasile Pascalau, Andreea Camarasan, Mihaela-Mirela Muresan, Ovidiu Laurean Pop, Roxana Brata
{"title":"血脂异常对未控制糖尿病患者临床特征的影响。","authors":"Lorena Paduraru, Andrei Vasile Pascalau, Andreea Camarasan, Mihaela-Mirela Muresan, Ovidiu Laurean Pop, Roxana Brata","doi":"10.21873/invivo.14020","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Current evidence suggests that dyslipidemia in patients with diabetes mellitus is associated with multiple microvascular and macrovascular complications. The prolonged failure to achieve glycemic and lipid profile targets increases cardiovascular risk, mortality, and the costs associated with medical care. This study aimed to explore the correlations between dyslipidemia and glycemic control in patients with diabetes, evaluate variations in lipid profiles, examine the impact of dyslipidemia on diabetes-related complications and assess the effectiveness of lipid-lowering treatments.</p><p><strong>Patients and methods: </strong>A cohort observational study was conducted on 304 patients hospitalized at the Emergency County Hospital in Oradea, Bihor, located in Northwest Romania, over a two-year period from 2022 to 2023. The study included data on diabetes control (fasting blood glucose, HbA1c), associated conditions including diabetes complications, laboratory analyses-lipid profile, creatinine, urea, albuminuria-anthropometric data, and home medication.</p><p><strong>Results: </strong>In the group without dyslipidemia, the mean HbA1c value was 8.96±2.81, compared to 9.70±2.80 in the dyslipidemia group. The mean blood glucose level was 207.44±126.09 in the group without dyslipidemia and 257.77±140.68 in the dyslipidemia group (<i>p</i>=0.048). Coronary artery disease was significantly more common in patients with dyslipidemia (58.9%) than in those without (4.6%) (<i>p</i>=0.004). Uric acid levels were higher in patients with dyslipidemia (<i>p</i>=0.048). Lipid-lowering therapy reduced high lipid values, but a significant percentage of patients on treatment still exhibited elevated cholesterol, LDL, and triglyceride levels.</p><p><strong>Conclusion: </strong>In patients with poorly controlled diabetes, dyslipidemia associates with poorer glycemic control, greater obesity levels, cardiovascular diseases, particularly coronary artery disease and peripheral arterial disease, as well as chronic kidney disease. Despite treatment, the lipid profile continues to remain elevated.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2243-2258"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223665/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Impact of Dyslipidemia on the Clinical Profile of Patients With Uncontrolled Diabetes.\",\"authors\":\"Lorena Paduraru, Andrei Vasile Pascalau, Andreea Camarasan, Mihaela-Mirela Muresan, Ovidiu Laurean Pop, Roxana Brata\",\"doi\":\"10.21873/invivo.14020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>Current evidence suggests that dyslipidemia in patients with diabetes mellitus is associated with multiple microvascular and macrovascular complications. The prolonged failure to achieve glycemic and lipid profile targets increases cardiovascular risk, mortality, and the costs associated with medical care. This study aimed to explore the correlations between dyslipidemia and glycemic control in patients with diabetes, evaluate variations in lipid profiles, examine the impact of dyslipidemia on diabetes-related complications and assess the effectiveness of lipid-lowering treatments.</p><p><strong>Patients and methods: </strong>A cohort observational study was conducted on 304 patients hospitalized at the Emergency County Hospital in Oradea, Bihor, located in Northwest Romania, over a two-year period from 2022 to 2023. The study included data on diabetes control (fasting blood glucose, HbA1c), associated conditions including diabetes complications, laboratory analyses-lipid profile, creatinine, urea, albuminuria-anthropometric data, and home medication.</p><p><strong>Results: </strong>In the group without dyslipidemia, the mean HbA1c value was 8.96±2.81, compared to 9.70±2.80 in the dyslipidemia group. The mean blood glucose level was 207.44±126.09 in the group without dyslipidemia and 257.77±140.68 in the dyslipidemia group (<i>p</i>=0.048). Coronary artery disease was significantly more common in patients with dyslipidemia (58.9%) than in those without (4.6%) (<i>p</i>=0.004). Uric acid levels were higher in patients with dyslipidemia (<i>p</i>=0.048). Lipid-lowering therapy reduced high lipid values, but a significant percentage of patients on treatment still exhibited elevated cholesterol, LDL, and triglyceride levels.</p><p><strong>Conclusion: </strong>In patients with poorly controlled diabetes, dyslipidemia associates with poorer glycemic control, greater obesity levels, cardiovascular diseases, particularly coronary artery disease and peripheral arterial disease, as well as chronic kidney disease. Despite treatment, the lipid profile continues to remain elevated.</p>\",\"PeriodicalId\":13364,\"journal\":{\"name\":\"In vivo\",\"volume\":\"39 4\",\"pages\":\"2243-2258\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223665/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"In vivo\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/invivo.14020\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14020","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
The Impact of Dyslipidemia on the Clinical Profile of Patients With Uncontrolled Diabetes.
Background/aim: Current evidence suggests that dyslipidemia in patients with diabetes mellitus is associated with multiple microvascular and macrovascular complications. The prolonged failure to achieve glycemic and lipid profile targets increases cardiovascular risk, mortality, and the costs associated with medical care. This study aimed to explore the correlations between dyslipidemia and glycemic control in patients with diabetes, evaluate variations in lipid profiles, examine the impact of dyslipidemia on diabetes-related complications and assess the effectiveness of lipid-lowering treatments.
Patients and methods: A cohort observational study was conducted on 304 patients hospitalized at the Emergency County Hospital in Oradea, Bihor, located in Northwest Romania, over a two-year period from 2022 to 2023. The study included data on diabetes control (fasting blood glucose, HbA1c), associated conditions including diabetes complications, laboratory analyses-lipid profile, creatinine, urea, albuminuria-anthropometric data, and home medication.
Results: In the group without dyslipidemia, the mean HbA1c value was 8.96±2.81, compared to 9.70±2.80 in the dyslipidemia group. The mean blood glucose level was 207.44±126.09 in the group without dyslipidemia and 257.77±140.68 in the dyslipidemia group (p=0.048). Coronary artery disease was significantly more common in patients with dyslipidemia (58.9%) than in those without (4.6%) (p=0.004). Uric acid levels were higher in patients with dyslipidemia (p=0.048). Lipid-lowering therapy reduced high lipid values, but a significant percentage of patients on treatment still exhibited elevated cholesterol, LDL, and triglyceride levels.
Conclusion: In patients with poorly controlled diabetes, dyslipidemia associates with poorer glycemic control, greater obesity levels, cardiovascular diseases, particularly coronary artery disease and peripheral arterial disease, as well as chronic kidney disease. Despite treatment, the lipid profile continues to remain elevated.
期刊介绍：
IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management.
The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
